LISATA THERAP.INC.DL-001 - Asset Resilience Ratio

Latest as of December 2025: 0.00%

LISATA THERAP.INC.DL-001 (8NE) has an Asset Resilience Ratio of 0.00% as of December 2025. The Asset Resilience Ratio measures the percentage of a company's total assets that are held in liquid form (cash and short-term investments). This metric indicates how well-positioned the company is to handle unexpected financial challenges, economic downturns, or strategic opportunities without requiring external financing. Read how much debt does LISATA THERAP.INC.DL-001 carry for a breakdown of total debt and financial obligations.

Liquid Assets

€0.00

≈ $0.00 USD Cash + Short-term Investments

Total Assets

€17.74 Million

≈ $20.74 Million USD All company assets

Resilience Assessment

Low

Financial Resilience Level

Asset Resilience Ratio Trend (2021–2025)

This chart shows how LISATA THERAP.INC.DL-001's Asset Resilience Ratio has changed over time. See LISATA THERAP.INC.DL-001 (8NE) net assets for net asset value and shareholders' equity analysis.

Liquid Assets Composition Over Time

This chart breaks down LISATA THERAP.INC.DL-001's liquid assets into cash & equivalents and short-term investments, showing how the composition has evolved over time. For market capitalisation and broader financial context, see 8NE company net worth.

Current Liquid Assets Breakdown

Component	Amount	% of Total Assets
Cash & Equivalents	€0.00	0%
Short-term Investments	€0.00	0%
Total Liquid Assets	€0.00	0.00%

Asset Resilience Insights

Limited Liquidity: LISATA THERAP.INC.DL-001 maintains only 0.00% of assets in liquid form.
This low level may indicate efficient asset utilization but could pose risks during economic downturns.
The company maintains a balanced mix of cash and short-term investments.

LISATA THERAP.INC.DL-001 Industry Peers by Asset Resilience Ratio

Compare LISATA THERAP.INC.DL-001's asset resilience ratio with other companies in the same industry.

Company	Industry	Asset Resilience Ratio
Xizang Haisco Pharmaceutical Group Co Ltd SHE:002653	Biotechnology	2.21%
CSL Ltd AU:CSL	Biotechnology	0.41%
Sk Biopharmaceuticals Co Ltd KO:326030	Biotechnology	0.14%
Crispr Therapeutics AG NASDAQ:CRSP	Biotechnology	74.05%
Tubize-Fin BR:TUB	Biotechnology	0.05%
Ascendis Pharma AS F:A71	Biotechnology	0.00%
Innovita Biological Technology Co. Ltd. A SHG:688253	Biotechnology	65.12%
Hyundai Bioscience Co. Ltd KQ:048410	Biotechnology	13.57%

Annual Asset Resilience Ratio for LISATA THERAP.INC.DL-001 (2021–2025)

The table below shows the annual Asset Resilience Ratio data for LISATA THERAP.INC.DL-001.

Year	Asset Resilience Ratio (%)	Liquid Assets	Total Assets	Change
2025-12-31	0.00%	€0.00 ≈ $0.00	€17.74 Million ≈ $20.74 Million	--
2024-12-31	42.96%	€15.04 Million ≈ $17.58 Million	€35.00 Million ≈ $40.92 Million	-8.13pp
2023-12-31	51.09%	€27.94 Million ≈ $32.67 Million	€54.69 Million ≈ $63.94 Million	+0.33pp
2022-12-31	50.76%	€37.07 Million ≈ $43.34 Million	€73.03 Million ≈ $85.38 Million	-21.73pp
2021-12-31	72.49%	€70.32 Million ≈ $82.21 Million	€97.01 Million ≈ $113.41 Million	--

pp = percentage points

About LISATA THERAP.INC.DL-001

F:8NE Germany Biotechnology

Market Cap

$27.89 Million

€23.86 Million EUR

Market Cap Rank

#24510 Global

#2124 in Germany

Share Price

€2.62

Change (1 day)

-1.50%

52-Week Range

€1.50 - €4.34

All Time High

€183.30